Anti-Human HLA-DQ (MHC Class II) [Clone 1a3] — Purified in vivo GOLD™ Functional Grade
Anti-Human HLA-DQ (MHC Class II) [Clone 1a3] — Purified in vivo GOLD™ Functional Grade
Product No.: H262
Clone 1a3 Target HLA-DQ Formats AvailableView All Product Type Monoclonal Antibody Alternate Names HLA-DQ Monomorphic Isotype Mouse IgG2a Applications ELISA , FC , in vivo , IP , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Unknown Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737520 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this HLA-DQ (Clone 1a3) antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this HLA-DQ (Clone 1a3) antibody for use in western blotting is 1-10 μg/ml. ELISA Additional Applications Reported In Literature ? IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 1a3 recognizes a monomorphic epitope on human HLA-DQ1. It does not cross-react with HLA-DR or HLA-DP. Background HLA-DQ antibody, clone 1a3, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DQ isotype (HLA-DQ). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DQ consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DQA1 and HLA-DQB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. Specific alleles of HLA-DQ are associated with autoimmune diseases, including celiac disease8 and type 1 diabetes9, and graft-versus-host disease10. Antigen Distribution HLA-DQ is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells. Ligand/Receptor CD3/TCR, CD4 PubMed NCBI Gene Bank ID Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The clone 1a3 is not explicitly mentioned in the context of in vivo mouse studies in the provided search results. However, clone 1a3 is known to react with human HLA-DQ and is used in Western blotting applications, reacting with virtually all B-cell lines and some tissue macrophages and dendritic cells. It does not react with HLA-DR. Another unrelated study mentions the use of a reprogramming cocktail denoted as 1a3 in the context of converting mouse fibroblasts into induced hepatic stem cells (iHepSCs), but this is not related to the clone 1a3 used for reacting with HLA-DQ. For specific details on how clone 1a3 is used in in vivo mouse studies related to HLA-DQ, additional information would be needed. The correct storage temperature for a sterile packaged monoclonal antibody such as clone 1a3 is typically between 2°C and 8°C (refrigerated conditions) for short-term storage, according to widely accepted laboratory standards for monoclonal antibodies. For short-term storage (up to several weeks), keep the antibody at 2–8°C (in a refrigerator). For long-term storage (several months or longer), it is best stored at -20°C or -80°C to maximize stability and prevent degradation. Key details:
If the sterile packaging refers to sterilized items in general (not antibodies), general standards for sterile medical item storage recommend keeping the temperature between 18°C and 23°C with 30–60% relative humidity to maintain packaging integrity. If you have a specific manufacturer's datasheet for clone 1a3, always follow those instructions, as some products may have unique requirements. Summary: For most sterile packaged monoclonal antibodies, store refrigerated at 2–8°C unless the manufacturer specifies otherwise. For general sterile items, store at 18–23°C. Several commonly used antibodies and proteins are frequently used alongside the 1a3 antibody (typically referring to anti-Rap1A, clone 1D4-1A3) in the literature, depending on the experimental context and application.
Summary of commonly used antibodies and proteins with 1a3:
These combinations enable multiplexing, validation, and broader mechanistic studies in cell biology, immunology, and protein biochemistry research. I cannot provide comprehensive key findings for clone 1A3 based on the available search results, as they contain limited and fragmented information about this specific clone. From the search results provided, I found only two brief mentions of clone 1A3, each in different research contexts: Nanopen Technology for Antibody DiscoveryIn one study focused on single B cell antibody discovery, clone 1A3 was associated with nanopen 928, which demonstrated changes in intensity and size during a screening process over a 45-minute timepoint. This appears to be part of research on rapid antibody discovery techniques using nanotechnology platforms. Myomaker Function in Cell FusionIn muscle biology research, clone 1A3 was identified as one of three myomaker knockout (KO) clones (along with 1B1 and 1B5) that could differentiate into muscle cells, as evidenced by myosin staining, but failed to undergo cell fusion. This suggests that myomaker protein is essential for the fusion process in muscle cell development. The search results do not provide sufficient detail about clone 1A3's specific characteristics, experimental outcomes, or broader scientific significance. To obtain comprehensive findings about clone 1A3 citations in scientific literature, additional search results containing more complete research articles and citations would be necessary. References & Citations1. Shookster L, et al. (1987) Hum Immunol. 20(1):59-70 2. Holling TM, Schooten E, van Den Elsen PJ. (2004) Hum Immunol. 65(4):282-90 3. Mitaksov V, Fremont DH. (2006) J Biol Chem. 281(15):10618-25 4. Wieczorek M, et al. (2017) Front Immunol. 8:292 5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921 6. Barnaba V, et al (1994) Eur J Immunol. 24(1):71-5 7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60 8. Castaño L, et al. (2004) J Pediatr Gastroenterol Nutr. 39:80–84 9. Cucca F, et al. (1993) Hum Immunol. 37:85 –94 10. Petersdorf EW, (1996) Proc Natl Acad Sci USA. 93(26):15358-63 11. Matsuoka T, et al. (2001) J Immunol. 166(4): 2202–2208 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-118 | |
M1188 | |
C247 | |
F1175 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
H135 | |
H136 | |
H137 | |
H1528 | |
H1530 | |
H1532 | |
H138 | |
H262 | |
H242 | |
H462 | |
90016 |
